Satoru Ikezawa

Pharmacological interventions for social cognitive impairments in schizophrenia: A systematic review and network meta-analysis of randomized controlled trials

Yuji Yamada, Norio Watanabe, Yui Tomo, H. Tachimori et autres

BACKGROUND: Social cognitive impairments are a fundamental aspect of schizophrenia, exerting a substantial influence on patients' functional outcomes. However, to date, there have been no meta-analyses of comprehensive pharmacological interventions covering all domains of social cognition. The aim of the present study …

jp (code pays fourni par la source)

Understanding the burden of cognitive impairment associated with schizophrenia: Results from the international LUCIA study

Christoph U. Correll, Silvana Galderisi, Maite Artés, Ana Fernández et autres

BACKGROUND: Cognitive impairment associated with schizophrenia (CIAS) is a prevalent, meaningful feature of schizophrenia with limited real-world data on its recognition and care setting impact. The LUCIA initiative is an international multi-stakeholder study that explored awareness, assessment practices, and the burden of …

de, us, it, Égypte, tw, cn, jp, se, be, au, at, no, nl, gb (code pays fourni par la source)

Awareness and management of cognitive impairment associated with schizophrenia in psychiatrists and patients: Results from a cross-sectional survey

Tomiki Sumiyoshi, Satoru Ikezawa, Tatsuro Marumoto, Ichiro Kusumi et autres

This study evaluated awareness, management, and the burden of cognitive impairment associated with schizophrenia (CIAS) in Japan. A non-interventional, cross-sectional study was conducted online between April and December 2023, involving 149 psychiatrists and 852 patients. Psychiatrists prioritized controlling positive symptoms in the …

jp (code pays fourni par la source)

Factor structure of social cognition in schizophrenia: Investigation of four core domains

Ryotaro Kubota, Takashi Uchino, Ryo Okubo, Hisashi Akiyama et autres

jp (code pays fourni par la source)

VALUABLE INTERACTION WITH COGNITIVE REMEDIATION AND OPTIMAL ANTIPSYCHOTICS FOR RECOVERY IN SCHIZOPHRENIA (VICTORY-S): STUDY PROTOCOL FOR AN INTERVENTIONAL, OPEN-LABEL, RATER- BLINDED, RANDOMIZED COMPARISON OF COMBINED TREATMENT WITH COGNITIVE REMEDIATION AND LURASIDONE OR PALIPERIDONE

Ryotaro Kubota, Satoru Ikezawa, Hideki Oi, Mari S. Oba et autres

Abstract Background Cognitive impairment, a core feature of schizophrenia, is associated with poor functional outcomes. Available interventions include both pharmacotherapy and psychosocial treatment. However, each of these interventions, when used alone, have often inadequate effect sizes. Aims & Objectives This study aims …

jp (code pays fourni par la source)

International perspective on social cognition in schizophrenia: current stage and the next steps

Sílvia Corbera, Matthew M. Kurtz, Amélie M. Achim, Giulia Agostoni et autres

In the last decades, research from cognitive science, clinical psychology, psychiatry, and social neuroscience has provided mounting evidence that several social cognitive abilities are impaired in people with schizophrenia and contribute to functional difficulties and poor clinical outcomes. Social dysfunction is a …

us, de, es, ca, it, fr, jp (code pays fourni par la source)

Clinical subtypes of schizophrenia based on the discrepancies between objective performance on social cognition tasks and subjective difficulties in social cognition

Takashi Uchino, Hisashi Akiyama, Ryo Okubo, Izumi Wada et autres

Intervention for social cognition could be key to improving social functioning in patients with schizophrenia. A first step towards its clinical implementation involves interviewing patients about their subjective difficulties with social cognition as they experience them in the real world. The present …

jp (code pays fourni par la source)

The feasibility and effectiveness of remote cognitive training on cognitive function and work performance in workers

Michi Shibaoka, Masashi Masuda, Satoko Iwasawa, Satoru Ikezawa et autres

Objectives: We aimed to determine whether remote cognitive training (CT) is feasible and has the potential to improve cognitive function and work performance in Japanese workers. Methods: From June to September 2020, this intervention time series study enrolled workers aged 18-65 years …

jp (code pays fourni par la source)

CONNEX, a Phase III Randomized Trial Program Assessing Efficacy and Safety of Iclepertin in Schizophrenia: Recruitment and Baseline Characteristics

Zuzana Blahova, Satoru Ikezawa, Peter Falkai, John Harrison Krystal et autres

Aims Glutamatergic signalling deficits contribute to the neuropathology of cognitive symptoms in schizophrenia. Iclepertin (BI 425809), a glycine transporter-1 inhibitor, enhances N-methyl-D-aspartate receptor signalling in the brain by increasing synaptic levels of its co-agonist glycine. The Phase III CONNEX programme aims to …

at, jp, de, us, gb (code pays fourni par la source)

International Experience of Implementing Cognitive Remediation for People With Psychotic Disorders

Frances Louise Dark, Isabelle Amado, Matthew D. Erlich, Satoru Ikezawa

BACKGROUND: Cognitive remediation (CR) is an effective therapy for the cognitive impact of mental illness, especially schizophrenia. Global efforts are being made to implement CR into routine mental health services with the aim of improving functional outcomes for the population of people …

au, fr, us, jp (code pays fourni par la source)

Preliminary data from the CONNEX-X extension trial examining the long-term safety of iclepertin in patients with schizophrenia who completed Phase III CONNEX trials

Corey Reuteman-Fowler, Zuzana Blahova, Steve Marder, Satoru Ikezawa et autres

Introduction Cognitive impairment associated with schizophrenia (CIAS) is an important unmet need as there are no effective treatments available. Iclepertin (BI 425809), a glycine transporter-1 inhibitor, has been shown to improve CIAS in Phase II trials, and Phase III trials are underway. …

de, fr, at, us, jp (code pays fourni par la source)

The Phase III CONNEX programme assessing the efficacy and safety of iclepertin in patients with schizophrenia: Trial design and recruitment update

Corey Reuteman-Fowler, Zuzana Blahova, Satoru Ikezawa, Steve Marder et autres

Introduction In a 12-week, Phase II (NCT02832037) trial, iclepertin (BI 425809), an inhibitor of glycine transporter-1, was generally well tolerated and significantly improved cognition in 509 patients with schizophrenia. Objectives The Phase III CONNEX programme aims to confirm the efficacy, safety and …

fr, at, jp, us, de (code pays fourni par la source)